* Note: Prices are in Million (M) USD.
Description:
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $305 M
Debt : $451 M
EBITDA : $207 M
Net Debt (Debt - Cash): $146 M
Since Net Debt is covered by EBITDA within 1 year, 3 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 20.73
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $40 M
Average Revenue: $148 M
Revenue Converted To Free Cash Flow (%): 27%
Avg Free Cash Flow Growth Per Year (Last 5 Years): -0.65%
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $359 M
Revenue 4 Years Ago (2020-12-31): $337 M
Last 5 Years Average Revenue Growth: 1%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $74 M
Share Count 5 Years Ago (2020-12-31): $114 M
Company is buying back its own shares, 3 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $1.39
Trailing 12-Month Earnings Per Share (EPS): $0.59
Average Earnings Per Share (EPS): $0.99
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -8%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $21
52-Week Low: $17
Threshold Price (15% Above 52-Week Low): $19
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $1,266 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 20 points to above Innoviva Inc (INVA) stock.
Last 8 Years Avg PE (Limited to last 8 years of EPS data) 9.72, Fair Value PE 25, Industry Based PE is 20 and Growth based PE is 8. Based on these all values average assigned is 15.68.
Value-Trades has assined P/E value 15.68. Since an average (Current Year EPS + Next Year EPS) earning per share is $0.99.
The fair value of Innoviva Inc (INVA) stock should be (15.68 x $0.99) = $15.52
